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Introduction 
Network meta-analyses (NMAs) assess the comparative effects of two or more 
interventions, even if they have not been compared head-to-head in a trial.1 The validity of 
NMAs is founded on the assumption of transitivity, i.e., that effects modifiers do not 
significantly differ across the included trials.1 The popularity of NMAs on pharmacological 
or non-pharmacological interventions is increasing in psychiatry.2 Recent NMAs have even 
combined pharmacological and non-pharmacologic interventions in the same network. 
Although this may be highly informative for guidelines development, it is methodologically 
challenging, and could compromise the validity of NMAs. We thus set out to evaluate NMAs 
that combined pharmacological and non-pharmacological interventions and provide some 
guidance on how to conduct them.  
 
Methods 
We searched Pubmed, PsycInfo, Embase, OVID Medline, Biological abstracts, Biosis 
and Web of Science until 31.08.2018. We appraised NMAs of RCTs based on the approach 
proposed by Cope et al.,3 focusing on: a) how the control node (or neutral comparator) was 
defined in the network geometry; b) differences between pharmacological and non-
pharmacological studies with respect to patient characteristics; c) distribution of risk of bias 
(RoB) in the network. According to the Cope’s approach, we checked if the impact of these 
issues on results was explored in the retained NMAs (See eMethods for more details).    
 
Results 
We retrieved 12 unique NMAs  (See eReferences). Eight were published between 
2017 and 2018; 6 focused on adults, 5 on children/adolescents, and one on both. These 
NMAs covered several psychiatric conditions, including major depressive disorder, anxiety 
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disorders, ADHD, OCD, bulimia nervosa, At Risk Mental State, and post-stroke depression 
(See eTable).  
Five NMAse1-3,e5,e6,e9, pooled different types of control conditions (e.g., placebo pill, 
psychological placebo, sham intervention) into the same node of the network, assuming that 
these comparators have similar effects. However, this hypothesis should be empirically 
tested, via meta-regression (when feasible) or subgroup/sensitivity analysis. Only two NMAs 
did soe2,e3,e9. 
Existing difference between pharmacological and non-pharmacological studies in 
patient characteristics for baseline disease severity or previous exposure to treatment was 
reported in only three NMAse8,e9,e11, and only one assessed its impact on the resultse9. The 
heterogeneity of patient characteristics was unclear or had not been retrieved from primary 
studies in most of the NMAs.   
 We found three NMAse8,e9,e11 in which the risk of performance or detection bias was 
not distributed evenly across pharmacological and non-pharmacological studies. Compared to 
pharmacological trials, those of non-pharmacological interventions were less likely to have 
participants, care givers and outcome assessors blinded, which is often an unavoidable 
limitation as some non-pharmacological treatments cannot always be masked. Four 
NMAse1,e2,e10,e11 performed sensitivity analysis to assess the impact of high RoB for lack of 
blinding on the treatment effects, but for most of the NMAs data were too sparse to draw any 
conclusion.     
 
Discussion 
NMAs combining pharmacological and non-pharmacological interventions for 
psychiatric conditions may be particularly prone to the violation of the transitivity 
assumption, which may affect their validity. The definition and classification of the control 
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node in the geometry of the network could impact the results of the NMA. A novel approach, 
called component NMA, could address this issue as it explores the treatment effects of 
interventions with multiple components.4 Furthermore, differences in baseline participants 
characteristics, study RoB and level of blinding may represent a limitation of NMA 
combining pharmacological and non-pharmacological therapies.5 Individual Participant Data 
NMA could overcome these limitations as it allows exploring treatment-patient interactions, 
to check RoB and obtain extra data from trialists.6 
We conclude that caution is needed when pharmacological and non-pharmacological 
interventions are combined in a NMA and specific potential limitations of this type of NMAs 
should always be systematically and transparently discussed. 
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